Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
Public ClinicalTrials.gov record NCT03364153. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with autosomal recessive Stargardt disease 1 (STGD1).
Study identification
- NCT ID
- NCT03364153
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 121 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 12, 2018 (Actual)
- Primary completion
- Mar 31, 2025 (Actual)
- Completion
- Mar 31, 2025 (Actual)
- Last update posted
- Apr 15, 2026
2018 – 2025
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Retinal Research Institute | Phoenix | Arizona | 85053 | — |
| Jules Stein Eye Institute/ David Geffen School of Medicine | Los Angeles | California | 90095 | — |
| VitreoRetinal Associates | Gainesville | Florida | 32607 | — |
| Retina Specialty Institute | Pensacola | Florida | 32503 | — |
| Wilmer Eye Institute, Johns Hopkins | Baltimore | Maryland | 21287 | — |
| Ophthalmic Consultants of Boston | Boston | Massachusetts | 02114 | — |
| University of Michigan/Kellogg Eye Center | Ann Arbor | Michigan | 48105 | — |
| The Retina Center | Minneapolis | Minnesota | 55404 | — |
| Retina Center of NJ, LLC. | Bloomfield | New Jersey | 07003 | — |
| Casey Eye Institute/Oregon Health & Science University | Portland | Oregon | 97239 | — |
| Wills Eye Hospital/Mid Atlantic Retina | Philadelphia | Pennsylvania | 19107 | — |
| UPMC Eye Center | Pittsburgh | Pennsylvania | 15213 | — |
| Palmetto Retina Center | West Columbia | South Carolina | 29169 | — |
| Austin Retina Associates | Austin | Texas | 78705 | — |
| Retina Foundation of the Southwest | Dallas | Texas | 75231 | — |
| Strategic Clinical Research Group | Willow Park | Texas | 76087 | — |
| University of Utah John A. Moran Eye Center | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03364153, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 15, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03364153 live on ClinicalTrials.gov.